Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Non-Current Liabilities: 2023-2025

Historic Total Non-Current Liabilities for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $7.7 million.

  • BioLineRx's Total Non-Current Liabilities fell 61.61% to $7.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.7 million, marking a year-over-year decrease of 61.61%. This contributed to the annual value of $10.0 million for FY2024, which is 26.79% up from last year.
  • As of Q2 2025, BioLineRx's Total Non-Current Liabilities stood at $7.7 million, which was down 10.47% from $8.6 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Total Non-Current Liabilities ranged from a high of $25.4 million in Q2 2023 and a low of $7.2 million during Q1 2024.
  • Its 3-year average for Total Non-Current Liabilities is $14.9 million, with a median of $13.8 million in 2023.
  • In the last 5 years, BioLineRx's Total Non-Current Liabilities rose by 26.79% in 2024 and then tumbled by 61.61% in 2025.
  • BioLineRx's Total Non-Current Liabilities (Quarterly) stood at $7.9 million in 2023, then increased by 26.79% to $10.0 million in 2024, then tumbled by 61.61% to $7.7 million in 2025.
  • Its Total Non-Current Liabilities was $7.7 million in Q2 2025, compared to $8.6 million in Q1 2025 and $10.0 million in Q4 2024.